Editas Medicine, Inc. EDIT 深 滬
等待開盤 06-02 09:30:00 美东时间
3.455
-0.005
-0.14%
華盛通- 最 高3.51
- 今 開3.38
- 成交量 187.13万股
- 最 低 3.2902
- 昨 收 3.46
- 總市值 3.38亿
- 52周最高 4.5372
- 市盈率 靜 --
- 換手率 1.91%
- 52周最低 1.66
- 委 比 -51.85%
- 總股本 9790.63万
- 歷史最高 99.95
- 量 比 0.38
- 振 幅 6.35%
- 歷史最低 0.9101
- 每 手 1
- 風險率 0.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | VTIX飙升46%，获美国空军SBIR项目资金支持；360数科大涨25%
VTIX飙升46%，获美国空军SBIR项目资金支持；APPS大涨38%，财报强劲，美银称其增长前景清晰；360数科大涨25%，用户规模稳步扩容，信贷投放有所收缩>>
05-28 19:22
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.
05-27 22:51
Editas Medicine Prices $125M Public Offering Of 55.6M Shares And Warrants At $2.25 Each
Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its
05-26 21:08
Editas Medicine stock dips on proposed equity offering
Editas Medicine (EDIT) shares fell nearly -12% premarket on Tuesday after the gene editing company launched an underwritten public offering of its common stock (or pre-funded warrants to purchase shar...
05-26 18:53
BUZZ-Editas Medicine tumbles after launching equity offering
BUZZ-Editas Medicine tumbles after launching equity offering ** Gene editing firm Editas Medicine EDIT.O shares down 16.3% in premarket trading on Tues to $2.31 as it looks to raise equity ** Cambridge, Massachusetts EDIT commences offering of stock, or pre-funded warrants, and accompanying warrants
05-26 18:39
Editas Medicine Launches Public Stock Offering to Raise Capital
Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten public offering of its common stock
05-26 18:19
Editas Reports Cholesterol-Lowering Results for Experimental Gene Therapy
Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, presented new preclinical data for EDIT-401, its lead in vivo development
05-26 18:11
Editas Medicine Announces Proposed Public Offering
Editas Medicine, a gene editing company, has initiated an underwritten public offering of its common stock and accompanying warrants. Cantor and Wells Fargo Securities are serving as joint book-running managers. The offering is subject to market conditions and is being conducted under an effective shelf registration statement on Form S-3. A preliminary prospectus supplement will be available on the SEC’s website. Editas Medicine is focused on dev...
05-26 10:15
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
Editas Medicine presented promising preclinical data for EDIT-401, showing ≥90% reductions in LDL-C, Lp(a), and ApoB in non-human primates, supporting its potential as a best-in-class gene editing medicine for hyperlipidemia. The company plans to submit a Clinical Trial Notification (CTN) in Australia by mid-2026 and aims to achieve early human proof-of-concept data by year-end, advancing its goal to address multiple cardiovascular risk factors t...
05-26 10:01
Editas Medicine Announces New Preclinical Data Supporting Continued Advancement Of Its In Vivo Development Candidate, EDIT-401, And Its Potential As A One-Time Treatment For Hyperlipidemia
The data is being presented this week at the 2026 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Boston, including one oral presentation and two poster presentations, as well as one oral
05-14 18:09
